MA30815B1 - Medicament combine - Google Patents

Medicament combine

Info

Publication number
MA30815B1
MA30815B1 MA31822A MA31822A MA30815B1 MA 30815 B1 MA30815 B1 MA 30815B1 MA 31822 A MA31822 A MA 31822A MA 31822 A MA31822 A MA 31822A MA 30815 B1 MA30815 B1 MA 30815B1
Authority
MA
Morocco
Prior art keywords
combined medicine
combination
agent
invention involves
her2 inhibitor
Prior art date
Application number
MA31822A
Other languages
English (en)
Inventor
Yoshikazu Ohta
Toshiya Tamura
Shinji Takagi
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA30815B1 publication Critical patent/MA30815B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UN AGENT PHARMACEUTIQUE CONTENANT UN INHIBITEUR DE HER2 ET UN AGENT THÉRAPEUTIQUE HORMONAL OU UN AGENT ANTICANCÉREUX EN COMBINAISON. LA PRÉSENTE INVENTION CONCERNE UN AGENT PHARMACEUTIQUE CONTENANT (1) UN INHIBITEUR DE HER2 PRÉSENTANT UN SQUELETTE PYRROLOPYRIMIDINE OU UN SQUELETTE PYRAZOLOPYRIMIDINE, ET (2) UN AGENT THÉRAPEUTIQUE HORMONAL OU UN AGENT ANTICANCÉREUX EN COMBINAISON.
MA31822A 2006-10-06 2009-04-27 Medicament combine MA30815B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006275841 2006-10-06
JP2007057902 2007-03-07

Publications (1)

Publication Number Publication Date
MA30815B1 true MA30815B1 (fr) 2009-10-01

Family

ID=39283276

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31822A MA30815B1 (fr) 2006-10-06 2009-04-27 Medicament combine

Country Status (23)

Country Link
US (1) US20100008912A1 (fr)
EP (2) EP2063895A2 (fr)
JP (1) JP2010505745A (fr)
KR (1) KR20090094804A (fr)
CN (1) CN101553222A (fr)
AR (1) AR063152A1 (fr)
AU (1) AU2007307489A1 (fr)
BR (1) BRPI0717477A2 (fr)
CA (1) CA2665692A1 (fr)
CL (1) CL2007002878A1 (fr)
CO (1) CO6180429A2 (fr)
CR (1) CR10759A (fr)
EA (1) EA200970353A1 (fr)
EC (1) ECSP099311A (fr)
GE (1) GEP20115218B (fr)
IL (1) IL197883A0 (fr)
MA (1) MA30815B1 (fr)
MX (1) MX2009003660A (fr)
NO (1) NO20091628L (fr)
PE (1) PE20080977A1 (fr)
TN (1) TN2009000119A1 (fr)
TW (1) TW200823218A (fr)
WO (1) WO2008044782A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MEP8409A (en) * 2004-06-02 2011-12-20 Fused heterocyclic compound
US20100183604A1 (en) 2007-06-19 2010-07-22 Takeda Pharmaceutical Company Limited Preventive/remedy for cancer
US8946239B2 (en) 2008-07-10 2015-02-03 Duquesne University Of The Holy Spirit Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
WO2011040212A1 (fr) 2009-10-01 2011-04-07 Takeda Pharmaceutical Company Limited Agent thérapeutique pour une tumeur cérébrale
KR101592258B1 (ko) * 2014-06-20 2016-02-05 보령제약 주식회사 제제 및 이의 제조방법
US10317014B2 (en) * 2016-08-09 2019-06-11 Baker Hughes, A Ge Company, Llc Flow variation system
EP4121130A4 (fr) * 2020-03-17 2024-03-27 MicroVention, Inc. Agents d'embolisation liquides

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU33730B (en) * 1967-04-18 1978-02-28 Farmaceutici Italia Process for preparing a novel antibiotic substance and salts thereof
JPS6019790A (ja) * 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
WO1989006692A1 (fr) * 1988-01-12 1989-07-27 Genentech, Inc. Procede de traitement de cellules tumorales par inhibition de la fonction receptrice du facteur de croissance
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
EP1545533A1 (fr) * 2002-09-04 2005-06-29 Schering Corporation Pyrazolopyrimidines utiles en tant qu'inhibiteurs de kinases dependantes des cyclines
JP4366683B2 (ja) 2003-07-28 2009-11-18 武原 力 熱サイホン
MEP8409A (en) * 2004-06-02 2011-12-20 Fused heterocyclic compound
MXPA06013952A (es) 2004-06-04 2007-02-08 Smithkline Beecham Cork Ltd Metodo para el tratamiento de cancer.
JP5334414B2 (ja) * 2004-09-06 2013-11-06 バイエル インテレクチュアル プロパティー ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規のピラゾロピリミジン
JP2006275841A (ja) 2005-03-30 2006-10-12 Taiheiyo Cement Corp セメント中のジエチレングリコール量の定量方法
JP2007057902A (ja) 2005-08-25 2007-03-08 Seiko Epson Corp 画像形成装置

Also Published As

Publication number Publication date
US20100008912A1 (en) 2010-01-14
CL2007002878A1 (es) 2008-08-01
EP2063895A2 (fr) 2009-06-03
MX2009003660A (es) 2009-04-22
BRPI0717477A2 (pt) 2015-06-16
KR20090094804A (ko) 2009-09-08
WO2008044782A2 (fr) 2008-04-17
ECSP099311A (es) 2009-06-30
WO2008044782A3 (fr) 2008-12-11
NO20091628L (no) 2009-06-26
EA200970353A1 (ru) 2009-10-30
TN2009000119A1 (en) 2010-10-18
EP2359825A2 (fr) 2011-08-24
AU2007307489A1 (en) 2008-04-17
IL197883A0 (en) 2009-12-24
CO6180429A2 (es) 2010-07-19
AR063152A1 (es) 2008-12-30
CN101553222A (zh) 2009-10-07
TW200823218A (en) 2008-06-01
GEP20115218B (en) 2011-05-25
JP2010505745A (ja) 2010-02-25
CR10759A (es) 2009-05-27
CA2665692A1 (fr) 2008-04-17
PE20080977A1 (es) 2008-09-05

Similar Documents

Publication Publication Date Title
CY1107906T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει παραγωγα οιστετρολης για χρηση στην θεραπεια κατα του καρκινου
ATE413162T1 (de) Pharmazeutische zusammensetzungen zur sicheren verabreichung von bei der behandlung von drogenabhängigkeit verwendeten arzneimitteln
TW200635923A (en) Tricyclic heterocycles, their manufacture and use as pharmaceutical agents
WO2008028965A3 (fr) Inhibiteurs de la protéine phosphatase 1, de gadd34 et du complexe protéine phosphatase 1/gadd34, leur préparation et leurs applications
MA29675B1 (fr) Nouvelle formulation pharmaceutique contenant un biguanide et un derive de thiazolidinedione
PL1680128T3 (pl) Heksafosforan mio-inozytolu do stosowania miejscowego
DE602005023203D1 (de) Zur verhinderung von missbrauch entworfene, feste arzneimittelform zur oralen verabreichung
EA200970353A1 (ru) Комбинированное лекарственное средство
NL300728I1 (fr)
WO2007062093A3 (fr) Polytherapie pour le traitement du cancer
EP1729817A4 (fr) Systeme de delivrance de gene contenant le gene de la relaxine et composition pharmaceutique utilisant la relaxine
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
MA27418A1 (fr) Ensemble de distribution de medicament.
WO2004071385A3 (fr) Utilisation de dipyridamole en association avec de l'acide acetylsalicylique et un antagoniste de l'angiotensine ii aux fins de la prevention des accidents cerebro-vasculaires
EA200501565A1 (ru) Предназначенная для перорального приёма лекарственная форма для антагонистов протонного насоса
WO2007009691A3 (fr) Combinaison de substances active s
BE1016292A3 (nl) Verbinding en gebruik bij behandeling.
ECSP066649A (es) Preparado efervescente de una sustancia básica farmacéuticamente activa
WO2005084671A3 (fr) Combinaison de voriconazole et d'un inhibiteur de cyp2c19 antifongique
UY31684A (es) Farmaco combinado
GB0313386D0 (en) Treatment of disease
DE50005282D1 (de) Medikament sowie aufeinander abgestimmte kombination von medikamenten
SV2006002017A (es) Piperazinas derivadas de urea
ATE459376T1 (de) Pharmazeutische formulierung und darin enthaltende liganden; uea-1 mimetika
WO2006043031A3 (fr) Traitement du cancer